---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product comparison"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product comparison. Topics: Lanifibranor: company statement of its position among PPAR agonists, Approved and phase 3 competitors named by Inventiva in its annual report, Lanifibranor with GLP-1 receptor agonists: company presentation of potential synergy, Resmetirom (REZDIFFRA): indication and accelerated approval, and 29 further topics. 33 evidence topics quoted from 30 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/product-comparison"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Lanifibranor: company statement of its position among PPAR agonists

> “Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ.”
> “While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH.”

Source: [Inventiva AASLD 2026 abstracts release (2026)](https://inventivapharma.com/wp-content/uploads/INVENTIVA-AALSD-Abstracts-PR-EN-10.6.2026-1.pdf)

<a id="topic-2.1.2.14-2"></a>

### Approved and phase 3 competitors named by Inventiva in its annual report

> “In March 2024, Madrigal received FDA approval of Rezdiffra for the treatment of patients with MASH with moderate to advanced liver fibrosis and received a conditional marketing authorization from the European Commission in August 2025.”
> “For example, Boehringer Ingelheim, Eli Lilly, Akero Therapeutics (a subsidiary of Novo Nordisk), GSK and Roche and 89bio are also evaluating their respective investigational MASH medications in Phase 3 clinical trials in patients with non-cirrhotic MASH and in patients with cirrhotic MASH.”
> “Other companies, including Sagimet, Boston Pharmaceuticals, Altimmune, AstraZeneca, Eli Lilly, NorthSea, Terns, Viking, BMS, Pfizer, and Regeneron and Gilead Sciences have drug candidates for the treatment of MASH that are in less advanced clinical or pre-clinical development stages.”
> “We may lose lanifibranor’s Fast Track Designation if the FDA concludes that Rezdiffra and/or Wegovy addresses the unmet medical need for patients with MASH.”
> “For example, lanifibranor has caused weight gain in certain patients and the potential for this side effect may, if approved, lead patients to prefer a GLP-1 agent for the treatment of MASH.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.14-3"></a>

### Lanifibranor with GLP-1 receptor agonists: company presentation of potential synergy

> “Potential synergy between pan-PPAR and GLP-1 reduces metabolic burden and fibrogenic drive”
> “Weight loss-independent PPAR benefit with weight-dependent mechanism of GLP-1s”
> “MASH drug selection will be on this background”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.1.2.14-4"></a>

### Resmetirom (REZDIFFRA): indication and accelerated approval

> “REZDIFFRA® is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).”
> “This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.”
> “Avoid use of REZDIFFRA in patients with decompensated cirrhosis”

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

### Resmetirom: mechanism of action, partial thyroid hormone receptor-beta agonist

> “Resmetirom is a partial agonist of the thyroid hormone receptor-beta (THR-β).”
> “THR-β is the major form of THR in the liver, and stimulation of THR-β in the liver reduces intrahepatic triglycerides, whereas actions of thyroid hormone outside the liver, including in heart and bone, are largely mediated through THR-α.”

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

### Resmetirom: oral once-daily dosing based on body weight

> “The recommended dosage of REZDIFFRA is based on actual body weight.”
> “<100 kg, the recommended dosage is 80 mg orally once daily.”
> “≥100 kg, the recommended dosage is 100 mg orally once daily.”
> “Concomitant use of REZDIFFRA with strong CYP2C8 inhibitors (e.g., gemfibrozil) is not recommended”

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

### Resmetirom: month 12 histology in Trial 1 (NCT03900429), 888 F2 and F3 participants, missing biopsy counted as nonresponse

> “The efficacy of REZDIFFRA was evaluated based on an efficacy analysis at Month 12 in Trial 1 (NCT03900429), a 54-month, randomized, double-blind, placebo-controlled trial.”
> “The month 12 analysis included 888 F2 and F3 (at eligibility) patients randomized 1:1:1 to receive placebo (n = 294), REZDIFFRA 80 mg once daily (n = 298), or REZDIFFRA 100 mg once daily (n = 296), in addition to lifestyle counseling on nutrition and exercise.”
> “Two pathologists, Pathologist A and Pathologist B, independently read the liver biopsies for each patient.”
> “Patients with missing liver biopsy at Month 12 are considered a non-responder.”

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

| Endpoint at month 12 | Placebo (N=294) | REZDIFFRA 80 mg (N=298) | REZDIFFRA 100 mg (N=296) |
| --- | --- | --- | --- |
| Resolution of steatohepatitis and no worsening of liver fibrosis, Pathologist A (%) | “13” | “27” | “36” |
| Difference vs. placebo (95% CI), Pathologist A | Not applicable | “14 (8, 20)” | “23 (16, 30)” |
| Resolution of steatohepatitis and no worsening of liver fibrosis, Pathologist B (%) | “9” | “26” | “24” |
| Difference vs. placebo (95% CI), Pathologist B | Not applicable | “17 (11, 23)” | “15 (9, 21)” |
| Improvement in liver fibrosis and no worsening of steatohepatitis, Pathologist A (%) | “15” | “23” | “28” |
| Difference vs. placebo (95% CI), Pathologist A | Not applicable | “8 (2, 14)” | “13 (7, 20)” |
| Improvement in liver fibrosis and no worsening of steatohepatitis, Pathologist B (%) | “13” | “23” | “24” |
| Difference vs. placebo (95% CI), Pathologist B | Not applicable | “11 (5, 17)” | “11 (5, 17)” |

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

### Resmetirom: MAESTRO-NASH week 52 primary analysis population of 966 participants

> “We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]).”
> “Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo). Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo).”
> “Diarrhea and nausea were more frequent with resmetirom than with placebo.”
> “(Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.)”

Source: [Harrison et al. (2024)](https://www.nejm.org/doi/full/10.1056/NEJMoa2309000)

<a id="topic-2.1.2.14-9"></a>

### Semaglutide (WEGOVY): MASH indication and accelerated approval

> “For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies (14.4)]. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.”

Source: [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

### Semaglutide: mechanism of action, GLP-1 receptor agonist

> “Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.”
> “For treatment of MASH in humans, the precise mechanism of action of semaglutide is not fully understood and may involve multiple pathways mediated by weight loss and other factors.”

Source: [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

### Semaglutide: subcutaneous once-weekly maintenance dosing for MASH

> “The recommended maintenance dosage of WEGOVY injection for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults is 2.4 mg injected subcutaneously once weekly. If patients do not tolerate the maintenance dosage of 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly.”

Source: [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)

<a id="topic-2.1.2.14-12"></a>

### Semaglutide: week 72 histology in Study 11 (NCT04822181), 800 F2 and F3 participants, reference-based multiple imputation

> “The efficacy of WEGOVY injection was evaluated based on an efficacy analysis at Week 72 in Study 11 (NCT#04822181), a 240-week, randomized, double-blind, placebo-controlled trial.”
> “The Week 72 analysis included 800 F2 and F3 (at eligibility) patients randomized 1:2 to receive placebo (n=266) or WEGOVY once weekly (n=534), in addition to standard of care for cardiometabolic comorbidities and healthy lifestyle counseling.”
> “Estimated using pooled Mantel-Haenszel (MH) estimates stratified by baseline type 2 diabetes status (presence or absence) and baseline fibrosis stage (F2 or F3) with missing data handled by reference-based multiple imputation”
> “Patients treated with WEGOVY injection (mean baseline body weight 95.4 kg) achieved an average of 10.5% weight loss from baseline at Week 72, and patients treated with placebo (mean baseline weight 97.6 kg) achieved an average of 2% weight loss from baseline at Week 72”

Source: [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)

| Endpoint at week 72 | Placebo (N=266) | WEGOVY injection (N=534) | Difference vs. placebo (95% CI) |
| --- | --- | --- | --- |
| Resolution of steatohepatitis and no worsening of liver fibrosis, response rate (%) | “34” | “63” | “29 (21, 36)” |
| Improvement in liver fibrosis and no worsening of steatohepatitis, response rate (%) | “22” | “37” | “14 (8, 21)” |
| Resolution of steatohepatitis and improvement in liver fibrosis, response rate (%) | “16” | “33” | “17 (10, 23)” |

Source: [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)

<a id="topic-2.1.2.14-13"></a>

### Semaglutide: phase 3 part 1 interim analysis at week 72 in the first 800 of 1197 participants

> “In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1).”
> “Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001).”
> “Gastrointestinal adverse events were more common in the semaglutide group.”

Source: [Sanyal et al. (2025)](https://www.nejm.org/doi/full/10.1056/NEJMoa2413258)

<a id="topic-2.1.2.14-14"></a>

### Efruxifermin: acquisition of Akero Therapeutics by Novo Nordisk completed in December 2025

> “Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025”
> “today announced that Novo Nordisk’s acquisition of Akero, announced on 9 October 2025, has been completed.”
> “At the completion of the transaction, Akero became a wholly owned subsidiary of Novo Nordisk.”
> “Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease).”

Source: [Novo Nordisk Akero acquisition completion release (2025)](https://akerotx.com/wp-content/uploads/2025/12/pr251209-akero-closing.pdf)

<a id="topic-2.1.2.14-15"></a>

### Efruxifermin: phase 3 trial in F2 or F3 MASH (NCT06215716), registry record

> “This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efruxifermin (EFX) in subjects with non-cirrhotic nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 or 3 (F2 or F3).”

Source: [ClinicalTrials.gov NCT06215716](https://clinicaltrials.gov/study/NCT06215716)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Akero Therapeutics, Inc” |
| Status | “Recruiting” |
| Study start (actual) | “2023-12-01” |
| Primary completion (estimated) | “2033-02” |
| Enrollment (estimated) | “1650” |
| Primary outcome, cohort 1 | “Cohort 1 Only: Resolution of NASH/MASH and a ≥ 1 stage improvement in fibrosis” |
| Primary outcome | “Event-free survival” |

Source: [ClinicalTrials.gov NCT06215716](https://clinicaltrials.gov/study/NCT06215716)

<a id="topic-2.1.2.14-16"></a>

### Efruxifermin: HARMONY phase 2b week 24 histology, liver biopsy analysis set and full analysis set

> “HARMONY is a multicentre, randomised, double-blind, placebo-controlled, 96-week, phase 2b trial that was initiated at 41 clinics in the USA.”
> “In the LBAS (n=113), eight (20%) of 41 patients in the placebo group had an improvement in fibrosis of at least 1 stage and no worsening of NASH by week 24 versus 15 (39%) of 38 patients in the efruxifermin 28 mg group (risk ratio [RR] 2·3 [95% CI 1·1-4·8]; p=0·025) and 14 (41%) of 34 patients in the efruxifermin 50 mg group (2·2 [1·0-5·0]; p=0·036).”
> “Based on the FAS (n=128), eight (19%) of 43 patients in the placebo group met this endpoint versus 15 (36%) of 42 in the efruxifermin 28 mg group (RR 2·2 [95% CI 1·0-4·8]; p=0·033) and 14 (33%) of 43 in the efruxifermin 50 mg group (1·9 [0·8-4·3]; p=0·123).”

Source: [Harrison et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37802088/)

<a id="topic-2.1.2.14-17"></a>

### Pegozafermin: acquisition of 89bio by Roche, agreement in September 2025 and tender offer completed in October 2025

> “Basel, 18 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire 89bio, Inc. (Nasdaq: ETNB), a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases.”
> “89bio’s pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients (F2 and F3 stages) as well as cirrhotic patients (F4 stage).”
> “Roche to acquire 89bio for US$14.50 per share in cash at closing, representing a total equity value of approximately US$2.4 billion.”

Source: [Roche 89bio merger agreement release (2025)](https://www.roche.com/media/releases/med-cor-2025-09-18)

> “Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of 89bio, Inc.”
> “Following completion of the merger, 89bio will become a wholly owned subsidiary of Roche, and 89bio’s shares will cease to be traded on the Nasdaq Global Market.”
> “89bio is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG).”

Source: [Roche 89bio tender offer release (2025)](https://www.roche.com/media/releases/med-cor-2025-10-30)

<a id="topic-2.1.2.14-18"></a>

### Pegozafermin: ENLIGHTEN-Fibrosis phase 3 trial (NCT06318169), registry record

> “The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.”

Source: [ClinicalTrials.gov NCT06318169](https://clinicaltrials.gov/study/NCT06318169)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Hoffmann-La Roche” |
| Status | “Recruiting” |
| Study start (actual) | “2024-03-13” |
| Primary completion (estimated) | “2029-02” |
| Enrollment (estimated) | “1350” |
| Primary outcome | “Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of Steatohepatitis at Week 52” |
| Primary outcome | “Number of Participants With Resolution of Steatohepatitis Without Worsening of Fibrosis at Week 52” |
| Primary outcome | “Time to First Occurrence of Disease Progression” |

Source: [ClinicalTrials.gov NCT06318169](https://clinicaltrials.gov/study/NCT06318169)

<a id="topic-2.1.2.14-19"></a>

### Pegozafermin: ENLIVEN phase 2b week 24 histology, full analysis population with multiple imputation

> “In this phase 2b, multicenter, double-blind, 24-week, randomized, placebo-controlled trial, we randomly assigned patients with biopsy-confirmed NASH and stage F2 or F3 (moderate or severe) fibrosis to receive subcutaneous pegozafermin at a dose of 15 mg or 30 mg weekly or 44 mg once every 2 weeks or placebo weekly or every 2 weeks.”
> “Among the 222 patients who underwent randomization, 219 received pegozafermin or placebo. The percentage of patients who met the criteria for fibrosis improvement was 7% in the pooled placebo group, 22% in the 15-mg pegozafermin group (difference vs. placebo, 14 percentage points; 95% confidence interval [CI], −9 to 38), 26% in the 30-mg pegozafermin group (difference, 19 percentage points; 95% CI, 5 to 32; P = 0.009), and 27% in the 44-mg pegozafermin group (difference, 20 percentage points; 95% CI, 5 to 35; P = 0.008). The percentage of patients who met the criteria for NASH resolution was 2% in the placebo group, 37% in the 15-mg pegozafermin group (difference vs. placebo, 35 percentage points; 95% CI, 10 to 59), 23% in the 30-mg pegozafermin group (difference, 21 percentage points; 95% CI, 9 to 33), and 26% in the 44-mg pegozafermin group (difference, 24 percentage points; 95% CI, 10 to 37).”
> “Missing end-point data (for 28 patients) were imputed with the use of multiple imputation by means of logistic regression with all collected outcomes. The full analysis population included all the enrolled patients who had undergone randomization and received at least one dose of pegozafermin or placebo and who had confirmed fibrosis stage F2 or F3 (indicating moderate or severe fibrosis) and a nonalcoholic fatty liver disease activity score of at least 4 at baseline, as assessed on independent review by a three-pathologist panel.”

Source: [Loomba et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10718287/)

<a id="topic-2.1.2.14-20"></a>

### Efimosfermin alfa (GSK): once-monthly FGF21 analog in phase 3, FDA Breakthrough Therapy and EMA PRIME designations in April 2026

> “27 April 2026”
> “GSK plc (LSE/NYSE: GSK) today announced that efimosfermin, a once-monthly investigational liver therapy, has been granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) and Priority Medicines (PRIME) Designation by the European Medicines Agency (EMA) for the treatment of MASH.”
> “Efimosfermin is currently in phase III with the ZENITH-1 and ZENITH-2 trials investigating efficacy and safety in MASH patients with F2/F3 fibrosis. Phase III trials in MASH patients with F4 fibrosis are expected to start this year.”
> “Efimosfermin is an investigational, once-monthly subcutaneous injection of a long-acting variant of FGF21 that is designed to regulate key metabolic pathways to decrease liver fat, ameliorate liver inflammation, and reverse liver fibrosis in patients with MASH.”

Source: [GSK efimosfermin Breakthrough Therapy and PRIME designation release (2026)](https://www.gsk.com/en-gb/media/press-releases/gsk-s-investigational-liver-therapy-efimosfermin-receives-us-fda-breakthrough-therapy/)

<a id="topic-2.1.2.14-21"></a>

### Efimosfermin alfa: ZENITH-1 phase 3 trial in F2 or F3 MASH (NCT07221227), registry record

> “The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.”

Source: [ClinicalTrials.gov NCT07221227](https://clinicaltrials.gov/study/NCT07221227)

| Field | Quoted record |
| --- | --- |
| Sponsor | “GlaxoSmithKline” |
| Status | “Recruiting” |
| Study start (actual) | “2025-10-24” |
| Primary completion (estimated) | “2028-03-29” |
| Enrollment (estimated) | “1200” |
| Primary outcome | “Proportion of participants experiencing improvement in fibrosis by >=1 stage and no worsening of steatohepatitis at Week 52” |
| Primary outcome | “Time from randomization to an adjudicated composite liver-related clinical outcome” |

Source: [ClinicalTrials.gov NCT07221227](https://clinicaltrials.gov/study/NCT07221227)

<a id="topic-2.1.2.14-22"></a>

### Efimosfermin alfa: phase 2 trial in F2 or F3 MASH with a safety primary endpoint at week 24

> “Participants were randomly assigned 1:1 to efimosfermin 300 mg or placebo administered by subcutaneous injection every 4 weeks (Q4W) over 24 weeks, stratified by MASH fibrosis stage (F2 vs F3 stage).”
> “The primary endpoint was safety and tolerability (ie, treatment-emergent adverse events, changes from baseline to week 24 in blood pressure and heart rate, and the incidence of grade 3 and grade 4 laboratory abnormalities at week 24), analysed in all participants who received at least one dose.”
> “Between May 4, 2023, and March 22, 2024, of 1171 participants screened, 84 participants were randomly assigned to efimosfermin 300 mg Q4W (n=43) or placebo (n=41)”
> “Adverse events were reported in 29 (67%) of 43 participants receiving efimosfermin and 22 (55%) of 40 receiving placebo.”

Source: [Noureddin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41655584/)

<a id="topic-2.1.2.14-23"></a>

### Survodutide: LIVERAGE phase 3 trial in noncirrhotic F2 to F3 MASH (NCT06632444), registry record

> “A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis”

Source: [ClinicalTrials.gov NCT06632444](https://clinicaltrials.gov/study/NCT06632444)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Boehringer Ingelheim” |
| Status | “Recruiting” |
| Study start (actual) | “2024-10-14” |
| Primary completion (estimated) | “2031-12-27” |
| Enrollment (estimated) | “1800” |
| Primary outcome, part 1 | “Part 1: Resolution of MASH without worsening of liver fibrosis on MASH Clinical Research Network (CRN) fibrosis score” |
| Primary outcome, part 1 | “Part 1: At least a 1-point improvement in fibrosis stage with no worsening of MASH” |

Source: [ClinicalTrials.gov NCT06632444](https://clinicaltrials.gov/study/NCT06632444)

<a id="topic-2.1.2.14-24"></a>

### Survodutide: phase 2 week 48 histology in F1 to F3 MASH, 293 participants who received at least one dose

> “In this 48-week, phase 2 trial, we randomly assigned adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of survodutide at a dose of 2.4, 4.8, or 6.0 mg or placebo.”
> “A total of 293 randomly assigned participants received at least one dose of survodutide or placebo. Improvement in MASH with no worsening of fibrosis occurred in 47% of the participants in the survodutide 2.4-mg group, 62% of those in the 4.8-mg group, and 43% of those in the 6.0-mg group, as compared with 14% of those in the placebo group (P<0.001 for the quadratic dose-response curve as best-fitting model).”
> “improvement in fibrosis by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively.”
> “Adverse events that were more frequent with survodutide than with placebo included nausea (66% vs. 23%), diarrhea (49% vs. 23%), and vomiting (41% vs. 4%)”

Source: [Sanyal et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38847460/)

<a id="topic-2.1.2.14-25"></a>

### Tirzepatide: SYNERGY-Outcomes phase 3 master protocol in high-risk MASLD selected by noninvasive tests (NCT07165028), registry record

> “The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO.”

Source: [ClinicalTrials.gov NCT07165028](https://clinicaltrials.gov/study/NCT07165028)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Eli Lilly and Company” |
| Status | “Recruiting” |
| Study start (actual) | “2025-10-15” |
| Primary completion (estimated) | “2030-08” |
| Enrollment (estimated) | “4500” |
| Primary outcome | “Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes (MALO)” |

Source: [ClinicalTrials.gov NCT07165028](https://clinicaltrials.gov/study/NCT07165028)

<a id="topic-2.1.2.14-26"></a>

### Tirzepatide: SYNERGY-NASH phase 2 week 52 histology in F2 or F3 MASH, 190 randomized with missing biopsies imputed

> “We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks.”
> “Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42).”
> “(Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.)”

Source: [Loomba et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38856224/)

<a id="topic-2.1.2.14-27"></a>

### Pemvidutide: PERFORMA phase 3 trial in F2 to F3 MASH initiated in August 2026

> “Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on serious liver diseases, today announced that the company has begun enrolling patients in the PERFORMA Phase 3 trial evaluating the efficacy and safety of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH).”
> “The 52-week data readout from the trial is anticipated in 2029.”
> “The PERFORMA Phase 3 trial, a global, randomized, double-blind, placebo-controlled, parallel-group study of pemvidutide in patients with MASH was initiated in August 2026.”
> “The study includes two parallel cohorts; Cohort 1 will enroll approximately 990 patients and is designed to support the accelerated approval pathway based on a biopsy-assessed primary efficacy endpoint of MASH resolution and/or fibrosis improvement at 52 weeks. A second cohort will enroll approximately 800 patients with fibrosis as evidenced through non-invasive tests (NITs) to add to the safety dataset.”

Source: [Altimmune PERFORMA initiation release (2026)](https://altimmune.gcs-web.com/node/17931)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Altimmune, Inc.” |
| Status | “Recruiting” |
| Study start (actual) | “2026-07-30” |
| Primary completion (estimated) | “2028-12” |
| Enrollment (estimated) | “1800” |
| Arms | “Pemvidutide 1.8 mg” |
| Arms | “Pemvidutide 2.4 mg” |

Source: [ClinicalTrials.gov NCT07795164](https://clinicaltrials.gov/study/NCT07795164)

<a id="topic-2.1.2.14-28"></a>

### Pemvidutide: IMPACT phase 2b week 24 histology in F2 or F3 MASH, intention-to-treat population

> “IMPACT is an ongoing 48-week international, randomised, double-blind, placebo-controlled, phase 2b trial in patients with biopsy-confirmed MASH and fibrosis stage F2 or F3.”
> “The dual primary endpoints were MASH resolution without worsening of fibrosis or at least one stage liver fibrosis improvement without worsening of MASH at 24 weeks in the intention-to-treat population.”
> “MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1·2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0·0001), and 45 (52%) of 85 patients in the 1·8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0·0001). Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1·2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0·59), and 30 (36%) of 85 patients in the 1·8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0·27).”
> “Pemvidutide treatment met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks but did not meet the other primary endpoint of fibrosis improvement without worsening of MASH at this timepoint.”

Source: [Noureddin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41237796/)

<a id="topic-2.1.2.14-29"></a>

### Denifanstat: phase 3 FASCINATE-3 trial withdrawn and further MASH development deferred pending non-dilutive financing

| Field | Quoted record |
| --- | --- |
| Sponsor | “Sagimet Biosciences Inc.” |
| Status | “Withdrawn” |
| Why stopped | “Business decision” |
| Enrollment (actual) | “0” |

Source: [ClinicalTrials.gov NCT06594523](https://clinicaltrials.gov/study/NCT06594523)

> “Further MASH development to be undertaken only upon securing non-dilutive funding”
> “The Company anticipates that the denifanstat and resmetirom combination program will be ready to advance into Phase 2 in the second half of 2026. The Company will undertake no further clinical development in MASH until non-dilutive financing is achieved.”

Source: [Sagimet Biosciences strategic and corporate updates release (2026)](https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-provides-strategic-and-corporate-updates)

<a id="topic-2.1.2.14-30"></a>

### Denifanstat: FASCINATE-2 phase 2b week 52 histology in F2 or F3 MASH, intention-to-treat population

> “participants aged 18 years and older with biopsy-confirmed MASH and stage F2 or F3 fibrosis were randomly assigned (2:1) to receive either 50 mg oral denifanstat or placebo once per day for 52 weeks.”
> “In the ITT population, 42 (38%) of 112 participants in the denifanstat group had a 2-point or greater improvement in NAS without a worsening of fibrosis versus nine (16%) of 56 participants in the placebo group (common risk difference 21·0%, 95% CI 8·1-33·9; p=0·0035). 29 (26%) of 112 participants in the denifanstat group showed MASH resolution with a 2-point or greater improvement in NAS without a worsening of fibrosis compared with six (11%) of 56 participants in the placebo group (common risk difference 13·0%, 0·7-25·3; p=0·0173).”

Source: [Loomba et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39396529/)

<a id="topic-2.1.2.14-31"></a>

### Cross-trial comparison of histologic response: company presentation, with its caveat that results may not be comparable

> “Resolution of MASH and fibrosis improvement ≥ least 1 stage”
> “Compares favorably to other oral and injectable compounds”
> “Fibrosis improvement ≥ 1 stage with no worsening of MASH”
> “Resmetirom and semaglutide have been approved under accelerated approval by the FDA.”
> “No head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.1.2.14-32"></a>

### Cross-trial comparison of adiponectin change: lanifibranor, resmetirom, efruxifermin, and pegozafermin, with the authors’ caveat that results may not be comparable

> “Data from late-stage therapeutics in MASH were collected from publications.”
> “Among MASH therapeutics in clinical development, lanifibranor induces the largest reported increase in ADP, with substantial changes that correlate with histologic improvement in both MASH activity and fibrosis6.”
> “No head-to-head clinical trials amongst late stage agents have been conducted, results obtained from different published trials with different patient populations. Results may not be comparable.”

Source: [Rinella et al. (2026a)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-MASH-TAG-2026-final-version.pdf)

| Product (trial, time point) | Dose | Absolute change in adiponectin from baseline at end of treatment, µg/ml |
| --- | --- | --- |
| Lanifibranor (NATIVE, 24 weeks) | “800mg” | “+ 11.95 (8.97 to14.94)” |
| Lanifibranor (NATIVE, 24 weeks) | “1200mg” | “+ 17.12 (14.29 to 19.96)” |
| Resmetirom (MAESTRO-NASH, 52 weeks) | “80mg” | “+ 0.86 (0.19)” |
| Resmetirom (MAESTRO-NASH, 52 weeks) | “100mg” | “+ 1.1 (0.19)” |
| Efruxifermin (HARMONY, 24 weeks) | “28mg” | “+ 1.4(0.74 to 2.08)” |
| Efruxifermin (HARMONY, 24 weeks) | “50mg” | “+ 3.0(2.34 to 3.71)” |
| Pegozafermin (ENLIVEN, 24 weeks) | “15mg” | “+ 1.1(0.7)” |
| Pegozafermin (ENLIVEN, 24 weeks) | “30mg” | “+ 1.1(0.3)” |
| Pegozafermin (ENLIVEN, 24 weeks) | “44mg” | “+ 1.2 (0.4)” |

Source: [Rinella et al. (2026a)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-MASH-TAG-2026-final-version.pdf)

<a id="topic-2.1.2.14-33"></a>

### Network meta-analysis of 29 randomized trials including lanifibranor, with the authors’ stated limitations

> “We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.”
> “A total of 29 randomized controlled trials (n=9324) were included.”
> “Data from eligible studies were extracted as intention-to-treat (ITT) analyses.”
> “Pegozafermin (RR: 3.46, CrI: 1.54–11.15), cilofexor + firsocostat (RR: 2.67, CrI: 1.05–8.13), denifanstat (RR: 1.94, CrI: 1.04–4.04), survodutide (RR: 1.86, CrI: 1.18– 3.28), obeticholic acid (RR: 1.85, CrI: 1.30–2.75), tirzepatide (RR: 1.77, CrI: 1.17–2.94), resmetirom (RR: 1.64, CrI: 1.27–2.20), and semaglutide (RR: 1.51, CrI: 1.23–1.90) were statistically better than placebo in achieving ≥1 stage of fibrosis improvement without worsening MASH (Figure 3A).”
> “Pegozafermin (RR: 8.65, CrI: 2.63–59.42), survodutide (RR: 6.62, CrI: 3.13–17.97), tirzepatide (RR: 4.65, CrI: 2.31–10.66), efruxifermin (RR: 3.51, CrI: 1.83–8.17), liraglutide (RR: 3.23, CrI: 1.11–14.17), vitamin E + pioglitazone (RR: 3.03, CrI: 1.31–9.04), resmetirom (RR: 2.54, CrI: 1.86–3.55), pioglitazone (RR: 2.29, CrI: 1.41–4.03), denifanstat (RR: 2.03, CrI: 1.04–4.72), semaglutide (RR: 1.87, CrI: 1.60–2.24), and lanifibranor (RR: 1.93, CrI: 1.30–3.02) were statistically better than placebo in achieving MASH resolution without worsening fibrosis.”
> “First, we acknowledge the modest number of trials with direct comparisons between pharmacological therapies, and the small number of trials for each agent; hence, most comparisons between treatments were based on indirect evidence; head-to-head trials versus other drugs should be considered to validate our findings.”
> “Comparability between trials was further limited by their heterogeneity in design and population (eg, demographics and comorbidities).”

Source: [Souza et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12614381/)

| Treatment | SUCRA, fibrosis improvement ≥1 stage without worsening MASH |
| --- | --- |
| Pegozafermin | “79.92” |
| Denifanstat | “60.64” |
| Survodutide | “59.89” |
| Tirzepatide | “57.37” |
| Efruxifermin | “56.20” |
| Resmetirom | “50.14” |
| Semaglutide | “47.04” |
| Lanifibranor | “46.56” |

Source: [Souza et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12614381/)

Additional sources: [Mangia and Valenti (2025)](https://pubmed.ncbi.nlm.nih.gov/40815181/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
